$16.42
-4.76%Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Quality against peers; 50 is the peer median.
Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.
The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.
The next report, and the record against analysts' estimates.
Fundamentals: trailing twelve months to Sep 2026, from the latest 10-K and 10-Qs.
IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.
A reverse discounted-cash-flow model: the yearly growth in free cash flow over the next ten years that today's enterprise value pays for.
The price assumes growth well above the company’s recent revenue growth.
The same assumptions for every company, so the figure compares expectations rather than valuing any one: a 9% discount rate, then 2.5% growth for ever after year 10, from the latest trailing free cash flow. Not shown for banks and insurers, or without positive free cash flow.
The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.